Brookstone Capital Management Purchases 644 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Brookstone Capital Management lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,227 shares of the medical equipment provider’s stock after buying an additional 644 shares during the quarter. Brookstone Capital Management’s holdings in Zimmer Biomet were worth $842,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Washington Trust Advisors Inc. acquired a new stake in Zimmer Biomet during the 1st quarter valued at $30,000. Columbia River Financial Group LLC acquired a new stake in Zimmer Biomet during the 1st quarter valued at $30,000. Accent Capital Management LLC acquired a new stake in Zimmer Biomet during the 1st quarter valued at $35,000. Cullen Frost Bankers Inc. lifted its holdings in Zimmer Biomet by 1,452.4% during the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 305 shares during the last quarter. Finally, Hilltop National Bank acquired a new stake in Zimmer Biomet during the 2nd quarter valued at $42,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.39% of the stock is currently owned by company insiders.

Zimmer Biomet Stock Down 0.0%

ZBH stock opened at $103.14 on Friday. The company has a market cap of $20.43 billion, a PE ratio of 25.09, a price-to-earnings-growth ratio of 2.37 and a beta of 0.67. The business has a 50-day simple moving average of $101.86 and a 200 day simple moving average of $97.68. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $114.72. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s payout ratio is 23.36%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ZBH. Stifel Nicolaus raised their price target on Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a report on Friday, September 19th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a report on Friday. Canaccord Genuity Group reissued a “hold” rating and set a $101.00 target price on shares of Zimmer Biomet in a report on Wednesday. Rothschild & Co Redburn initiated coverage on Zimmer Biomet in a report on Thursday, September 18th. They set a “buy” rating and a $130.00 target price for the company. Finally, Redburn Partners set a $130.00 target price on Zimmer Biomet in a report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average target price of $111.94.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.